trending Market Intelligence /marketintelligence/en/news-insights/trending/vt0m8b7jlaytalp-iui8tw2 content esgSubNav
In This List

Reata drug improves kidney function in phase 2 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Reata drug improves kidney function in phase 2 study

Reata Pharmaceuticals Inc. said its medicine bardoxolone methyl significantly improved kidney function in an ongoing phase 2 study of patients with certain kidney diseases.

According to interim data from the Phoenix trial, patients with autosomal dominant polycystic kidney disease and IgA nephropathy who received bardoxolone showed large improvements in kidney function.

Autosomal dominant polycystic kidney disease is an inherited condition that causes fluid-filled sacs called cysts to develop in the kidneys. IgA nephropathy, also known as Berger's disease, is a disorder that forms clumps inside the kidneys' tiny filters, affecting the organ's ability to filter wastes from the blood.

There were no reported drug-related serious side effects and reported side effects were generally mild to moderate in intensity.

The Irving, Texas-based drugmaker, which focuses on oral anti-oxidative and anti-inflammatory drugs, said full data for the main goal of the study of change in estimated level of kidney function will be available in the third quarter.

Bardoxolone received priority review designation from the Japanese Ministry of Health, Labour and Welfare in March.